BPC-157 vs TB-500
Gastric Pentadecapeptide · Thymosin Beta-4 Fragment
Here is how these two compounds compare, based on published research, not marketing claims.
BPC-157
Tells the body to build new blood vessels right where the injury is.
TB-500
Signals the body's repair cells to move toward the damage.
BPC-157
212 studies
4 human trials
Not FDA-Approved
TB-500
1050 studies
13 human trials
Not FDA-Approved
What it does
BPC-157
In animal studies, drives new blood vessel formation at injury sites, one of the body's main repair signals in damaged tissue. A short peptide fragment originally isolated from human stomach juice that, in rodent models, ramps up production of growth factors involved in healing (VEGF, EGF, FGF). The angiogenic effect documented in those animal studies is what underlies the recovery claims that made BPC-157 prominent in athletic and post-surgical contexts. Published human evidence remains essentially absent.
TB-500
Typically a synthetic 4-amino-acid fragment of thymosin beta-4's active region (Ac-SDKP, the first four residues of the 43-amino-acid parent molecule), though commercial products labeled TB-500 vary in actual composition. Marketed as if interchangeable with full-length Tβ4, but the published human research is on the parent peptide, not the fragment. The mechanism described in animal studies (mobilization of repair cells through actin sequestration) is shared, but the evidence base for TB-500 specifically is a fraction of what exists for thymosin beta-4.
How it works
BPC-157
A copy of a small protein the body naturally makes in the stomach. It works by turning up three repair signals (VEGF, EGF, FGF) that tell the body to build new blood vessels. It also nudges the nitric oxide system, which controls blood flow and inflammation. In animal research, the result is the body's own repair process running faster.
TB-500
A copy of a fragment of a natural protein called Thymosin Beta-4. It works on actin, the scaffolding cells use to crawl through tissue. By turning up that scaffolding-rebuild process, the body's repair cells can migrate to where they're needed, and inflammatory signals get dialed down along the way.
How often
BPC-157
In studies, given as a daily shot under the skin, usually for several weeks at a time. Some studies have looked at oral forms specifically for gut work.
TB-500
In studies, given as a twice-weekly shot under the skin. The compound stays active in the body longer than BPC-157, which is why dosing is less frequent in protocols.
How strong
BPC-157
Local. The action concentrates at the injury rather than spreading body-wide.
TB-500
Body-wide. Unlike BPC-157's local action, TB-500's signal works wherever cells are migrating, which is anywhere repair is happening.
Main tradeoff
BPC-157
Strong animal data on tendons and gut healing. Human studies are thin. And one quirk: most of the published research traces back to a single research group, which limits how independent the findings are.
TB-500
Bigger total research base than BPC-157, including more human studies. The catch: most of that broader work is on the parent protein, Thymosin Beta-4, not the TB-500 fragment specifically. The two don't always behave the same way.
Best for
BPC-157
- Research on a specific local injury: tendons, ligaments, or gut lining
- Research targeting one site rather than a body-wide effect
- Research using daily subcutaneous injection
TB-500
- Research on systemic recovery across multiple sites
- Research into a body-wide repair signal rather than a localized one
- Research using twice-weekly dosing
How to choose
A good fit for BPC-157
- Research on a specific local injury: tendons, ligaments, or gut lining
- Research targeting one site rather than a body-wide effect
- Research using daily subcutaneous injection
A good fit for TB-500
- Research on systemic recovery across multiple sites
- Research into a body-wide repair signal rather than a localized one
- Research using twice-weekly dosing
Consider both across time
BPC-157 and TB-500 are usually studied as a pair, not as alternatives. They go after different parts of the same job: BPC-157 tells the body to build the supply lines (new blood vessels) that bring nutrients to the injury, and TB-500 signals the repair crew (the migrating cells) to get moving toward the damage. Used together, in animal research, the body has both the delivery system and the workforce activated at once. No controlled human trial of the specific combination has been published. The pair is sometimes called the Wolverine Stack.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Tissue Repair
- Tissue Repair connects to NO System Modulation
- NO System Modulation upregulates VEGF / EGF / FGF
- VEGF / EGF / FGF connects to Blood Vessel Formation
- Blood Vessel Formation connects to Nutrient Delivery
- Tissue Repair connects to Actin Regulation
- Actin Regulation promotes Cell Migration
- Cell Migration connects to Cytokine Reduction
- Cytokine Reduction connects to Cell Arrival at Injury
BPC-157 increases growth factors (VEGF, EGF, FGF) that signal the body to build new blood vessels at the injury site.
TB-500 regulates actin, the structural protein cells use to reorganize and migrate toward damaged tissue.
Research Evidence
Most of what we know about both peptides comes from animal research, where results are strong and consistent for tissue repair. Human data is thin for both. Animal results don't always translate to people cleanly, which is one reason neither is FDA-approved despite years of research.
- 1.
For research on a specific local injury (tendons, ligaments, or gut lining), BPC-157 is the closer fit. That's where the most consistent preclinical data sits.
- 2.
For research on systemic recovery or multi-site repair, TB-500 is the closer fit. Its cell-migration signal works wherever repair is happening.
- 3.
For research interested in the combination, the mechanistic logic is straightforward: BPC-157 tells the body to build the supply lines, TB-500 signals the repair crew to migrate. Animal protocols have examined the combination. Human controlled-trial data on the specific combination doesn't exist yet.
- 4.
Neither compound has the human trial data to back clinical efficacy claims. Both are research peptides. Anything stated about their effects in people is inference from animal work plus small pilot studies, not established fact.
Key Limitations
- •Both compounds lack completed randomized controlled trials in humans. Most efficacy evidence is preclinical, with limited human pilot data for both.
- •Most BPC-157 research traces back to a single research group, which limits independent replication.
- •TB-500 is a fragment of Thymosin Beta-4. Research on the parent protein doesn't transfer cleanly to the fragment.
- •The combination is widely discussed in non-scientific contexts but has minimal formal research support.
- •Neither compound has established dosing, pharmacokinetics, or bioavailability data in humans.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
BPC-157
"BPC-157 healed my gut issues in two weeks"
Plausible but unproven in humans
"BPC-157 fixed my tendon injury faster than anything"
Plausible but unproven in humans
"BPC-157 is completely safe with no side effects"
Insufficient evidence
TB-500
"TB-500 is the best peptide for systemic recovery after surgery"
Plausible but unproven
"Stacking TB-500 with BPC-157 covers both local and systemic healing"
Plausible but unproven
"It healed my torn rotator cuff without surgery"
Anecdotal only
Safety Comparison
Animal safety data on both is good: no major toxicity at doses used in studies. The honest gap: there are no large human safety studies for either, so anything claimed about long-term human safety is inference from animal work plus small pilot studies, not established fact.
BPC-157
Animal studies report favorable safety with no toxicity signals at doses used in research. Human safety data is limited. Long-term effects in people are not established.
TB-500
Animal studies have not flagged major toxicity. The evidence base is narrower than BPC-157's overall, but TB-500's parent compound (Thymosin Beta-4) has a longer human trial record in wound healing, which provides indirect signal.
What the Research Suggests
BPC-157 and TB-500 work on complementary parts of tissue repair, not competing ones. BPC-157 tells the body to build new blood vessels at injury sites. TB-500 signals repair cells to migrate to where they're needed. Both have good animal data and limited human data. Neither is FDA-approved. The honest summary: strong preclinical signals for each compound on its own, real human trial gap for both, and a mechanistic case for stacking that hasn't been formally tested in humans yet.